INTELLIGENT MICROSCOPE WORKSTATION FOR CANCER DIAGNOSIS

这份SBIR第一阶段提案由病理成像公司提交。 (图)本着1971年《国家癌症法》的精神，该法案赋予了卫生部。 卫生与公众服务部(然后是卫生、教育和福利部) 负责“加速将研究成果转化为 在1984-1990年间学术界(卡内基梅隆大学) 大学和南加州大学)使用180,000美元 库尔特生物医学研究机器人显微镜，Diff3/50，连接到 价值80,000美元的InterData Model 3230计算机，在一系列 美国国立卫生研究院累计资助100多万美元，实现了 滤泡性淋巴瘤分型的智能表现。由此产生的 系统，当与病理学家的专业视觉技能配合时 定位卵泡，所取得的性能远远超过 机器人或单独行动的病理学家。与此同时，太平洋投资公司资助了 减少自有5,000元电脑化摄影机的费用 具有与个人计算机的网络接口的数字显微镜。vbl.使用 这款相机和基于PC的图像分析软件由Kensal Consulting提供 (图森)与加州大学病理学系的一个联合项目 德克萨斯州，PIC在一天内复制了CMU/USC取得的结果。自.以来 患者样本太小，无法得出统计结论，这是 因此，这项提议的目的是申请资金进行一项 对100-200名患者进行的权威研究(是CMU/USC研究的五倍) 同时确定算法环境的健壮性 在分辨率、放大倍数、颜色等方面。 第一阶段的研究将简化为实践，并彻底测试 可以商业化生产和销售的CMU/USC癌症诊断 在第三阶段期间在全国范围内广泛使用，价格为15,000美元或 每单位更少。

This SBIR Phase I proposal is submitted by the Pathology Imaging Corp. (PIC) in the spirit of the National Cancer Act of 1971 which gave the Dept. of Health and Human Services (then Health, Education, and Welfare) the responsibility to "speed the translation of research results into widespread application." During 1984-1990 academia (Carnegie Mellon University and the University of Southern California) using the $180,000 Coulter Biomedical Research robot microscope, the diff3/50, interfaced to a $80,000 Interdata model 3230 computer, conducted research under a series of NIH grants cumulatively funded at over one million dollars which achieved intelligent performance in subtyping follicular lymphomas. The resulting system, when teamed with the expert visual skills of the pathologist in locating follicles, achieved performance far exceeding that of either the robot or the pathologist acting alone. At the same time PIC funded the reduction to practice of a proprietory $5,000 computerized camera for digital microscopy having a network interface to personal computers. Using this camera and PC-based image analysis software by Kensal Consulting (Tucson) in a joint project with the Department of Pathology, University of Texas, PIC reproduced IN ONE DAY the results achieved by CMU/USC. Since the patient sample was too small to draw statistical conclusions, it is therefore the purpose of this proposal to request funding to conduct a definitive study of 100-200 patients (five times that of the CMU/USC study) and simultaneously determine the robustness of the algorithmic environment with regard to resolution, magnification, color, etc. The aim of this Phase I research would be to reduce to practice and exhaustively test the CMU/USC cancer diagnosis which could be manufactured commercially and sold for widespread use nationwide during Phase III at a price of $15,000 or less per unit.